Literature DB >> 28205333

Longitudinal study of clinical prognostic factors in patients with early rheumatoid arthritis: the PREDICT study.

Paul Bird1, Dave Nicholls2, Rina Barrett3, Julien de Jager4, Hedley Griffiths5, Lynden Roberts6, Kathleen Tymms7, Philip McCloud8, Geoffrey Littlejohn6,9.   

Abstract

AIM: To assess the association between baseline clinical prognostic factors and subsequent Disease Activity Score of 28 joints (DAS28) remission in early rheumatoid arthritis (RA).
METHODS: Data were collected using point of care clinical software from participating rheumatology centres. Patients aged 18 years or over whose date of clinical onset of RA was within the previous 12-24 months, who had at least 6 months of follow-up data and a DAS28-ESR (erythrocyte sedimentation rate) score recorded between 12 and 24 months from first being seen for RA were included. Data collected included baseline demographics, mode of disease onset, pattern of joint involvement at onset, smoking status, DAS28, rheumatoid factor (RF), anti-citrullinated peptide antibodies (ACPA), time from symptom onset to presentation and disease activity at baseline. Univariate and multivariate logistic regression of DAS28-ESR remission between 12 and 24 months after first assessment were performed.
RESULTS: Data from 1017 patients were analyzed: 70% female; mean age 60 years (SD: 14.7); 70% RF-positive, 58% ACPA-positive. The strongest age and sex adjusted baseline predictors of DAS28-ESR remission at 12-24 months were remission at baseline (odds ratio [OR]: 4.49, 95% CI: 2.17-9.29, P < 0.001), being male (OR: 2.42, 95% CI: 1.46-4.01, P < 0.001), abstaining from alcohol (P < 0.001) and being lower weight (OR: 0.98, 95% CI: 0.97-1.00, P = 0.015). There was no statistically significant association between joint onset patterns, mode of onset, RF, ACPA or smoking status.
CONCLUSION: In this observational study, patients with early RA at risk of not achieving remission include those with high disease activity at baseline, women, those who drink alcohol and those with higher body weight.
© 2017 Asia Pacific League of Associations for Rheumatology and John Wiley & Sons Australia, Ltd.

Entities:  

Keywords:  prognostic factors; remission; rheumatoid arthritis; rheumatoid factor

Mesh:

Substances:

Year:  2017        PMID: 28205333     DOI: 10.1111/1756-185X.13036

Source DB:  PubMed          Journal:  Int J Rheum Dis        ISSN: 1756-1841            Impact factor:   2.454


  7 in total

1.  Autoantibodies against a novel citrullinated fibrinogen peptide related to smoking status, disease activity and therapeutic response to methotrexate in cuban patients with early rheumatoid arthritis.

Authors:  Goitybell Martínez; Eugen Feist; Maité Martiatu; Hilda Garay; Bárbara Torres
Journal:  Rheumatol Int       Date:  2020-05-29       Impact factor: 2.631

2.  Factors predicting addition of disease-modifying antirheumatic drugs after initial methotrexate monotherapy in patients with rheumatoid arthritis.

Authors:  Takashi Yamaguchi; Noriko Kohyama; Miki Takenaka; Takahiro Okada; Tatsuya Kurihara; Kosuke Sakurai; Yusuke Miwa; Mari Kogo
Journal:  Clin Rheumatol       Date:  2021-01-22       Impact factor: 2.980

3.  Changes in Alcohol Use and Associations With Disease Activity, Health Status, and Mortality in Rheumatoid Arthritis.

Authors:  Joshua F Baker; Bryant R England; Ted R Mikuls; Jesse Y Hsu; Michael D George; Sofia Pedro; Harlan Sayles; Kaleb Michaud
Journal:  Arthritis Care Res (Hoboken)       Date:  2020-02-12       Impact factor: 4.794

4.  Clinical predictors of remission and low disease activity in Latin American early rheumatoid arthritis: data from the GLADAR cohort.

Authors:  Rocio V Gamboa-Cárdenas; Manuel F Ugarte-Gil; Massardo Loreto; Mónica P Sacnun; Verónica Saurit; Mario H Cardiel; Enrique R Soriano; Cecilia Pisoni; Claudio M Galarza-Maldonado; Carlos Rios; Sebastião C Radominski; Geraldo da R Castelar-Pinheiro; Washington Alves Bianchi; Simone Appenzeller; Inés Guimarães da Silveira; Cristiano A de Freitas Zerbini; Carlo V Caballero-Uribe; Adriana Rojas-Villarraga; Marlene Guibert-Toledano; Francisco Ballesteros; Rubén Montufar; Janitzia Vázquez-Mellado; Jorge Esquivel-Valerio; Ignacio García De La Torre; Leonor A Barile-Fabris; Fedra Irazoque Palezuelos; Lilia Andrade-Ortega; Pablo Monge; Raquel Teijeiro; Ángel F Achurra-Castillo; María H Esteva Spinetti; Graciela S Alarcón; Bernardo A Pons-Estel
Journal:  Clin Rheumatol       Date:  2019-06-03       Impact factor: 2.980

Review 5.  Smoking, alcohol consumption and disease-specific outcomes in rheumatic and musculoskeletal diseases (RMDs): systematic reviews informing the 2021 EULAR recommendations for lifestyle improvements in people with RMDs.

Authors:  Maud Wieczorek; James Martin Gwinnutt; Maxime Ransay-Colle; Suzanne Mm Verstappen; Francis Guillemin; Andra Balanescu; Heike Bischoff-Ferrari; Annelies Boonen; Giulio Cavalli; Savia de Souza; Annette de Thurah; Thomas Ernst Dorner; Rikke Helene Moe; Polina Putrik; Javier Rodríguez-Carrio; Lucía Silva-Fernández; Tanja A Stamm; Karen Walker-Bone; Joep Welling; Mirjana Zlatkovic-Svenda
Journal:  RMD Open       Date:  2022-03

Review 6.  Effects of physical exercise and body weight on disease-specific outcomes of people with rheumatic and musculoskeletal diseases (RMDs): systematic reviews and meta-analyses informing the 2021 EULAR recommendations for lifestyle improvements in people with RMDs.

Authors:  James M Gwinnutt; Maud Wieczorek; Giulio Cavalli; Andra Balanescu; Heike A Bischoff-Ferrari; Annelies Boonen; Savia de Souza; Annette de Thurah; Thomas E Dorner; Rikke Helene Moe; Polina Putrik; Javier Rodríguez-Carrio; Lucía Silva-Fernández; Tanja Stamm; Karen Walker-Bone; Joep Welling; Mirjana I Zlatković-Švenda; Francis Guillemin; Suzanne M M Verstappen
Journal:  RMD Open       Date:  2022-03

7.  Patient's perspective of sustained remission in rheumatoid arthritis.

Authors:  Irazú Contreras-Yáñez; Guillermo Guaracha-Basañez; Daniel Ruiz-Domínguez; Virginia Pascual-Ramos
Journal:  BMC Musculoskelet Disord       Date:  2017-09-02       Impact factor: 2.362

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.